Sun Young Min1, Sun Kyung Baek2*, Chi Hoon Maeng2, Jae Joon Han2 and Hong Jun Kim2
1Department of General Surgery, Kyung Hee University School of Medicine, South Korea
2Department of Internal Medicine, Kyung Hee University School of Medicine, South Korea
Background: Chemotherapy-induced Febrile Neutropenia (FN) is a major risk factor for infectionrelated morbidity and mortality during chemotherapy. We aimed to investigate the incidence of FN and its risk factors in breast cancer patients with (neo-) adjuvant anthracycline based chemotherapy.
Methods: Clinical, oncologic, and FN information of 125 women with early or locally advanced breast cancer receiving anthracycline-based chemotherapy as (neo-) adjuvant chemotherapy were retrospectively collected and analyzed in a single center.
Results: Thirty-four (27.2%) of 125 patients, with mean age 51.6 (Range: 35 to 77) years, suffered from FN. In univariate analysis, patients ≥ 65 years old [Odd Ratio (OR): 6.43, 95% confidence interval (95% CI): 2.16-19.16] and those 55 to 65 years old (OR: 4.68, 95% CI: 1.67-13.10) had a higher risk of FN. Patients with Body Surface Area (BSA) ≤ 1.45 m2 (OR: 6.78, 95% CI: 2.26-20.28) and those with Hypertension (HTN) (OR: 2.56, 95% CI: 1.05-6.21) had a higher risk of FN. In multivariate analysis, patients ≥ 65 years old (OR: 5.47, 95% CI: 1.52-19.69), those 55 to 65 years old (OR: 6.01, 95% CI: 1.81-19.93), and those with BSA ≤ 1.45 m2 (OR: 9.19, 95% CI: 2.68-31.48) had a higher risk of FN.
Conclusion: Besides age ≥ 65 years, age 55 to 65 years and low BSA ≤ 1.45 m2 were additional risk factors for FN. Therefore, prophylactic G-CSF support should be considered for breast cancer patients who would receive (neo-) adjuvant anthracycline based chemotherapy and have these risk factors to prevent chemotherapy-induced FN.
Adjuvant chemotherapy; Anthracycline; Breast cancer; Febrile neutropenia
Min SY, Baek SK, Maeng CH, Han JJ, Kim HJ. Risk Factors of Febrile Neutropenia in Early Breast Cancer Patients Receiving Anthracycline-based Chemotherapy. Clin Oncol. 2020;5:1763..